Neoadjuvant Chemotherapy, Pembrolizumab, Triple Negative Breast Cancer, Tumor Microenvironment
Conditions
Brief summary
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer. (Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Interventions
GENETICVisium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Triple negative breast cancer * Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not * Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy * Sign to informed consent
Exclusion criteria
* Patients with difficulty in obtaining sufficient samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genomic profiling will be assessed by tissue and blood samples(analyze the TME changes) | 3year | Tissue and blood will be tested for Spatial transcriptomics, WGS(Wilcoxon rank sum test or Chi-square test, cell-cell interaction) |
Countries
South Korea
Contacts
Primary ContactYeon Hee Park, MD, Ph.D
Outcome results
None listed